Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART

Journal of Clinical Virology

Volumn 48, Issue 3, 2010, Pages 162-167

  MacLeod, Iain J ^a   Rowley, Christopher F ^a,b   Thior, Ibou ^a   Wester, Carolyn ^a   Makhema, Joseph ^a   Essex, Max ^a   Lockman, Shahin ^a,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Drug resistance; HIV; Minor variant; Nevirapine; PMTCT

Indexed keywords

LAMIVUDINE; NEVIRAPINE; PLACEBO; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EXPOSURE; DRUG RESPONSE; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFANT; INFECTION PREVENTION; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERTICAL TRANSMISSION;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MUTATION, MISSENSE; NEVIRAPINE; PREGNANCY; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE;

EID: 77953213212     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.03.017     Document Type: Article

References (19)

1. WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. September 10, 2009.
2. Eshleman S.H., Mracna M., Guay L.A., Deseyve M., Cunningham S., Mirochnick M., et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 15 (2001) 1951-1957
3. Eshleman S.H., Hoover D.R., Chen S., Hudelson S.E., Guay L.A., Mwatha A., et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 19 (2005) 2167-2169
4. Martinson N.A., Morris L., Gray G., Moodley D., Pillay V., Cohen S., et al. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 44 (2007) 148-153
5. Jourdain G., Ngo-Giang-Huong N., Le Coeur S., Bowonwatanuwong C., Kantipong P., Leechanachai P., et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 351 (2004) 229-240
6. Johnson J.A., Li J.F., Morris L., Martinson N., Gray G., McIntyre J., et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 192 (2005) 16-23
7. Loubser S., Balfe P., Sherman G., Hammer S., Kuhn L., and Morris L. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 20 (2006) 995-1002
8. Palmer S., Boltz V., Martinson N., Maldarelli F., Gray G., McIntyre J., et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci USA 103 (2006) 7094-7099
9. Flys T., Nissley D.V., Claasen C.W., Jones D., Shi C., Guay L.A., et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 192 (2005) 24-29
10. Lockman S., Shapiro R.L., Smeaton L.M., Wester C., Thior I., Stevens L., et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 356 (2007) 135-147
11. Coovadia A., Hunt G., Abrams E.J., Sherman G., Meyers T., Barry G., et al. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis 48 (2009) 462-472
12. Shapiro R.L., Thior I., Gilbert P.B., Lockman S., Wester C., Smeaton L.M., et al. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS 20 (2006) 1281-1288
13. Thior I., Lockman S., Smeaton L.M., Shapiro R.L., Wester C., Heymann S.J., et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA 296 (2006) 794-805
14. Lallemant M., Jourdain G., Le Coeur S., Mary J.Y., Ngo-Giang-Huong N., Koetsawang S., et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 351 (2004) 217-228
15. Rowley C.F., Boutwell C.L., Lockman S., and Essex M. Improvement in allele-specific PCR assay with the use of polymorphism-specific primers for the analysis of minor variant drug resistance in HIV-1 subtype C. J Virol Methods 149 (2008) 69-75
16. Rowley C.F., Boutwell C.L., Lee E., MacLeod I.J., Ribaudo H., Essex M., et al. Ultrasensitive detection of minor drug resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance. AIDS Res Hum Retroviruses 26 (2010) 293-300
17. Lockman S, the A5208/Octane Study Team. Lopinavir/ritonavir + tenofovir/emtricitabine is superior to nevirapine + tenofovir/emtricitabine for women with prior exposure to single-dose nevirapine: A5208 ("OCTANE"). Paper presented at 16th conference on retroviruses and opportunistic infections, Montreal, Canada, February 8-11, 2009 [Abstract #94LB].
18. Palumbo P, Violari A, Lindsey J, Hughes M, Jean-Philippe P, Mofenson L, et al. Nevirapine (NVP) vs lopinavir-ritonavir (LPV/r)-based antiretroviral therapy (ART) in single dose nevirapine (sdNVP)-exposed HIV-infected infants: preliminary results from the IMPAACT P1060 trial. Paper presented at 5th IAS conference on HIV pathogenesis, treatment and prevention, 19-22 July, 2009 [Abstract LBPEB12].
19. Prendergast A., Mphatswe W., Tudor-Williams G., Rakgotho M., Pillay V., Thobakgale C., et al. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS 22 (2008) 1333-1343